Hims & Hers Health reported third-quarter results that topped Street expectations Monday and said it plans to release a ...
James Manning / PA Images / Getty Images After rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its third-quarter sales fell short of ...
GlobalData on MSN10d
Novo Nordisk signs $285m deal with Ascendis to create once-monthly GLP-1RANovo Nordisk and Ascendis Pharma have agreed to collaborate in developing metabolic and cardiovascular therapies, among them ...
MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...
This week, 60 Minutes traveled to Denmark to report on Novo Nordisk, the pharmaceutical company that's behind the popular drugs Wegovy and Ozempic. Novo Nordisk's success with these drugs has led ...
Novo Nordisk's blockbuster drugs Ozempic and Wegovy have slimmed down Hollywood stars and millions of non-celebrities worldwide — all while adding great heft to Denmark's economy. Novo Nordisk ...
Novo Nordisk and Ascendis Pharma have agreed to collaborate in developing metabolic and cardiovascular therapies, among them a once-monthly glucagon-like peptide receptor agonist (GLP-1RA).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback